CD8A and COVID-19: For example, tocilizumab treatment in severe-stage COVID-19 patients resulted in a high proportion of plasma B cells with antibody-secreting functions and we found that the cytotoxicity and cytokine production of effector CD8+ T cells remained stable upon tocilizumab treatment.